Thursday, December 28, 2006

Telik, A Biotech Blow Up

Why do I avoid biotech story stocks? Just take a look at Telik (Ticker: TELK), the company announced three phase 3 clinical trial results for Telcyta, an ovarian cancer drug and they all missed their primary endpoints. Talk about a striking out three times in a row! No matter how great the phase 1 and 2 clinical results are; you want to see positive phase 3 results before even considering going all in. It really is a gamble when you’re investing based on phase 1 and 2 clinical results. So be careful…

2 Comments:

At January 02, 2007, Anonymous hustlermoneyblog said...

wow!..kool site. I love all the ideas. If you like, we can trade links. Email me. thanks.

 
At January 02, 2007, Anonymous Anonymous said...

good blog!
thanks

please read my blog
about investing

rc
http://tradingtennis.blogspot.com

 

Post a Comment

<< Home